

**AHNCI Neurologic Oncology Program Tumor Board**

Friday, March 20, 2020

12:00-1:00 p.m.

Jho Conference Room, 6th Floor, AGH

Join Zoom Meeting

<https://zoom.us/j/519670691>

Meeting ID: 519 670 691

Dial by your location

+1 646 558 8656

**Cases to be discussed**

|  |  |  |  |
| --- | --- | --- | --- |
| **Case**  | **De-identified patient** | **Reason** | **Presenter** |
| 1 | LB MRN: 10003981 | 1. Stage I (T1 N0 M0) large-cell neuroendocrine carcinoma of the left lower lung lobe status post SBRT (48 Gy in 4 fractions) completed in January 2018 at UPMC2. Presenting now with altered mental status and left upper extremity paresis with evidence of a 3.2 x 2.5 cm lesion within the right thalamusReason for presenting: Radiology review and management discussion | SA |
| 2 | TK MRN: 718552 | Dx: Base of skull mass s/p biopsy --  preliminary showed plasmacytomaReason for Presenting: Discuss Pathology/Management | SA |
| 3 |  KE MRN: 11852420 | 41 y/o female who underwent brain biopsy at OSH. Path still pending. Presenting to discuss with rad onc/Neurosurgery. |  TR |
| 4 | FL MRN: 4570229 | 62 y/o male with abnormal MRI Brain with possible leptomeningeal carcinomatosis. History of medulloblastoma in 1981 and meningioma in 2015. Presenting to discuss with Neurosurgery |  TR |
| 5 |  JW MRN: 11737046 | 52 y/o male with left frontal brain mass on MRI 10/28/2019. CNS lymphoma vs. metastatic disease vs. demyelination disease. Patient to follow up with BMT | TR |
| 6 | DB MRN: 1892990 | 89 y/o male with left frontal atypical meningioma diagnosed 6/2017. Most recent recurrence 2/20/2020. Possible radiation necrosis noted on MRI Brain 3/17/20. Presenting to review imaging. | TR |
| 7 | ML MRN: 11843750 | New GBM patient screen for AGILE. |  TR |
| 8 |  BR MRN: 3320982 | New GBM patient screen for AGILE. | TR |
| 9 |  |  |  |
| 10 |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

Objectives: Upon completion of this activity, participants will have a better understanding of decision-making for complex Neurologic Oncology and be armed with clinical pathways to improve care.

Accreditation: Allegheny General Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement:Allegheny General Hospital designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit(s)™*.  Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Disclosure: In accordance with the Accreditation Council for Continuing Medical Education (ACCME) and the policy of Allegheny General Hospital, presenters must disclose all relevant financial relationships, which in the context of their presentation(s), could be perceived as a real or apparent conflict of interest, (e.g., ownership of stock, honoraria or consulting fees). Any identifiable conflicts will be resolved prior to the activity. Any such relationships will be disclosed to the learner prior to the presentation(s).

Moderators and Presenters: Tulika Ranjan, MD and Stephen Karlovits, MD has nothing to disclose

AHN CME Credit

**TEXT 412-301-9919**save this number to your contacts–
will use this **same** number every week to text your attendance

**Today’s SMS Code: QELYAP**

You must text within 24 hours of the start of tumor board. You will receive a text receipt and a link to confirm attendance and receive credit